NCT03858972 2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2 Terminated
Clinical Trials
11 trialsNCT03952325 2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT01064713 2018-07-17
Phase II Study of Tesetaxel in Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01221870 2012-07-24
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Genta Incorporated
Phase 2 Unknown
NCT01296243 2012-07-24
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Genta Incorporated
Phase 2 Unknown
NCT01573468 2012-07-24
TESEGAST
Genta Incorporated
Phase 2 Unknown
NCT01215877 2012-07-11
Tesetaxel for Previously Treated Patients With Bladder Cancer
Genta Incorporated
Phase 2 Unknown
NCT01609127 2012-06-01
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Genta Incorporated
Phase 2 Unknown
NCT00080834 2012-05-16
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
Daiichi Sankyo
Phase 2 Completed
NCT01095120 2012-03-15
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Genta Incorporated
Phase 2 Unknown
NCT01092585 2011-11-08
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Genta Incorporated
Phase 2 Unknown